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journal homepage: http: / /www.pediatr -neonatol .comEDITORIALMalignant Renal Tumors in ChildhoodMalignant renal tumors account for approximately 7% of
childhood malignancies, including favorable histology
Wilms’ tumor (WT), anaplastic WT, clear cell sarcoma of
the kidney (CCSK), malignant rhabdoid tumor (MRT), renal
cell carcinoma, congenital mesoblastic nephroma, and
other rare tumors.1 Favorable histology WT is the most
common tumor and has a 5-year overall survival of more
than 90%.2 Anaplastic WT, CCSK, MRT, and renal cell car-
cinoma have less favorable outcomes. Approximately 30%
of patients with pediatric renal tumors have survival rates
less than 70%, including those with relapsed favorable his-
tology WT, anaplastic WT, MRT, and renal cell carcinoma.
WT (nephroblastoma) is the second most common
intra-abdominal cancer and accounts for about 95% of all
renal tumors in childhood.3 About 75% of these patients
are younger than 5 years of age, with a peak incidence at
2e3 years of age. Surgery is the critical treatment for WT
and the addition of chemotherapy and, in certain cir-
cumstances, radiotherapy, gives a significant improve-
ment in survival rates. Survival, once less than 30%, is
currently greater than 90%, making it an excellent
example of therapeutic success resulting from an inter-
disciplinary approach and the cooperation of pediatric
surgeons, pediatric oncologists, pathologists, radiologists,
and radiotherapists. This dramatic improvement in sur-
vival is partly due to well-defined, risk-stratified treat-
ment protocols, which achieve the highest cure rates and
decrease acute and late toxicities. However, a high inci-
dence of p53 gene mutation in patients with anaplastic
WT may explain why these tumors do not respond well to
chemotherapy. A recent study has also identified a gain of
chromosome 1q as an adverse prognostic marker for
favorable histology WT.4 WT biology and treatment is in
progress and remains a paradigm for multimodal cancer
treatment. Future efforts will focus on the cellular
mechanisms of metastasis and on minimizing toxicity and
improving outcomes for patients with unfavorable histol-
ogy tumors and recurrent disease.
CCSK comprises 2e5% of all primary renal tumors and is
the second most common renal tumor in children.5 This
tumor is observed most often in children between 2 and 4
years of age and is described as having a high metastatic
potential.5 The treatment outcome for these patients has1875-9572/$36 Copyright ª 2014, Taiwan Pediatric Association. Publish
http://dx.doi.org/10.1016/j.pedneo.2014.01.003improved dramatically, with 5-year event-free survival and
overall survival of 79% and 86%, respectively, in recent
years after the use of more intensive chemotherapy.5 Stage
IV disease and young age (especially age less than 1 year)
are significant adverse prognostic factors for event-free
survival.5 Future directions should include the develop-
ment of targeted treatment based on specific molecular
aberrations in the consideration of direct and late toxicities
from intensified treatment.
MRT is a rare, highly aggressive cancer accounting for
only 2% of all renal tumors in childhood and is characterized
by young age and advanced stage at presentation.6,7 The
survival of patients with MRT is generally poor, with early
relapses and progression of the disease, even with use of
full chemotherapeutic and radiotherapeutic regimens. The
5-year event-free survival is 22% and the overall survival
26%.6 Younger age at diagnosis is an adverse prognostic
factor for survival.6 Optimized treatment, including target
therapies, is needed.
In this issue of Pediatrics and Neonatology, Jaing et al7
report the clinical manifestation and outcome of pediatric
patients with malignant renal tumors in a single institution
from 1991 to 2010. Fifty-four patients were studied,
including 42 with WT, seven with CCSK, and five with MRT.
Most patients underwent unilateral nephrectomy and lymph
node sampling followed by adjuvant chemotherapy.
Twenty-one patients subsequently received radiotherapy.
The collective median survival time of all patients was 88
months. For patients with WT and CCSK, the 5-year event-
free survival and overall survival were 83.3% and 85.7%,
respectively. Moreover, children less than 2 years of age at
diagnosis with WT or CCSK had a survival rate of 100%, in
contrast with the children with MRT, which is usually fatal
within 1 year of diagnosis. It may be interpreted that most
of the younger patients with WT or CCSK were diagnosed at
earlier stages.
A reduction in tumor volume resulting from preoperative
chemotherapy facilitated tumor removal by surgery and
might have prevented intraoperative tumor spill and the
deleterious effects of radiation in young children. In this
study, most patients with MRT were diagnosed in infancy or
presented with central nervous system metastases at
diagnosis. Treatment strategies need to be refined fored by Elsevier Taiwan LLC. All rights reserved.
160 Editorialpatients with MRT, although the number of cases analyzed
is too small to draw definitive conclusions.
In conclusion, this study showed good treatment out-
comes for patients with WT and CCSK; however, it is
essential to acknowledge its limitations, as it is a single
institutional study with a small cohort size.
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